Conclusions-The EnVision
Immunohistochemistry is nowadays an integral part of both the diagnostic process and research activity. However, there is a lack of standardisation of the techniques used and results can vary from laboratory to laboratory, making comparisons diYcult. Many technical factors contribute to this situation. First, the type of tissue available for immunohistochemistry is not always adequate because of problems with sampling or processing. Second, most if not all fixatives produce a certain degree of antigen masking by modifying the protein structure of the tissue. 1 2 Hence, immunophenotyping has mainly been performed on fresh tissue, though the fixation problems can be partly overcome by treating routine sections with proteolytic enzymes. [3] [4] [5] At the beginning of the 1990s, new techniques for antigen retrieval from routine sections were proposed, based on the use of heat. These rapidly gained ground because they had the following advantages: (1) they preserve cytological detail, (2) they are easy to use, (3) they enhance the sensitivity of immunohistochemical methods, and (4) their eVectiveness is almost independent of the fixative used. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Finally, the detection method chosen is crucial, since its sensitivity greatly influences the results. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] This is particularly important when dealing with routine material where the target availability can be very slight-either because of antigen masking or because the antigen is only present in trace amounts. In assessing the performance of immunohistochemical methods, the feasibility of using high dilutions of the primary antibody needs to be examined, since high sensitivity contributes to the specificity of the results and undoubtedly reduces the cost per test.
In this paper, we report on the results of a clinical trial of the recently introduced EnVision TM + system.
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Methods
THE EnVision
TM + SYSTEM EnVision TM + is a two step staining technique in which the primary antibody is followed by a polymeric conjugate in sequential steps. [23] [24] [25] [26] [27] [28] [29] [30] [31] The polymeric conjugate consists of a large number of peroxidase and secondary antibody molecules bound directly to an activated dextran backbone (fig 1) . The polymeric conjugates hold up to 100 enzyme molecules and up to 20 antibody molecules per backbone.
TISSUE SELECTION
For this study, a large series of samples from normal and pathological tissues was selected. The former comprised hyperplastic bone marrow, reactive lymph nodes, and placenta at term; the latter included granulomatous lymphadenitis, lymphomas belonging to the main categories of the REAL classification, 32 nonlymphoid leukaemias grouped according to the FAB classification, 33 primary or secondary carcinomas arising in the breast, small bowel, prostatic gland, endometrium, thyroid, and larynx, as well as retinoblastomas and rhabdomyosarcomas.
SAMPLE PROCESSING
The procedures diVered depending on the type of sample. In particular, the bone marrow biopsies were fixed in B5 for 2.30 hours, washed in 70% alcohol for 30 minutes, and then decalcified for 2.30 hours in bisodic salts of ethilendiaminotetracetic acid (EDTA); the lymph nodes were partly fixed in B5 for 3.0 hours and then washed in 70% alcohol, and partly fixed in 10% buVered formalin for periods ranging from 24 hours to one week. The last procedure (10% buVered formalin for 24 hours to one week) was also used for the remaining samples.
After fixation and possible decalcification, all specimens were washed in 70% alcohol and processed in a VIP 2000 machine (Miles Scientific, Bayer Divisione Diagnostica, Milan, Italy), with paraYn embedding (Merck Histologie® non-caking paraYn) at 56°C.
ROUTINE SECTION PRETREATMENT FOR ANTIGEN UNMASKING AND ANTIBODIES
For this trial, the antigen unmasking technique was defined according to the experience gained in the course of a previous study, where a series of antibodies had been applied at diVerent dilutions on routine sections from tissue samples fixed in 10% buVered formalin or B5, and from B5 fixed, EDTA decalcified bone marrow biopsies, 34 by using the APAAP, 35 LSAB, 36 and SABC 37 methods. Fifty three antibodies (listed in tables 1 and 2) were tested with the EnVision TM + system. They were diluted according to a chessboard titration method, starting from the highest dilution reached in the previous study. 22 The EnVision TM + system was used both manually and automatically, with horseradish peroxidase and diaminobenzedene hydrochloride (DAB) being the enzyme and chromogen employed. In the manual mode, the results were compared with those from the APAAP, 35 CSA, 38 LSAB, 36 and SABC 27 techniques performed at room temperature. With the automatic approach, the EnVision TM + system was used in a TechMate 500 (Biotech Solutions, Santa Barbara, California, USA), the results being compared to those obtained with the APAAP, LSAB, SABC, and ChemMate TM methods. When DAB was the chromogen, endogenous peroxidase activity was blocked by 3% hydrogen peroxide for 15 minutes at room temperature, in keeping with the characteristics of the ready-to-use solution included in the EnVision TM + package and with our previous experience, which had shown this approach to be eYcient when using critical samples such as bone marrow. 39 
COST OF THE DETECTION METHODS EMPLOYED
All the detection systems used for the present study were purchased from Dako A/S (Glostrup, Denmark). According to prices on the Italian market, the cost/test of the EnVision TM + system 23 31 was 20% higher than that of the corresponding reagents/kits for the APAAP, CSA, SAB, and SABC methods, while it was 40% cheaper then the ChemMate TM package.
RESULT EVALUATION
The following indices were considered in evaluating the results and comparing the EnVision TM + system with the other methods: (1) the type of immunoreactivity (staining intensity and specificity), and (2) the highest/ optimal dilution reachable with each antibody. The results were scored from − to ++++ according to the percentage of cells expected to be positive and the staining intensity.
Results
When manually applied and compared with the APAAP, LSAB, and SABC methods, the figs 2 and 3) . Remarkably, these results were also obtained with some antibodies which are known to give uncertain responses in formalin fixed material. Thus when applying the anti-CD5 monoclonal antibody to samples fixed for 24 hours, the EnVision TM + system provided clear cut staining of the neoplastic cells both in B cell chronic lymphocytic leukaemia and mantle cell lymphoma (six and five cases tested, respectively) (fig 4) , while the APAAP, LSAB, and SABC techniques gave rise to inconstant results since the positivity of the lymphomatous elements ranged from weak to null while that of reactive T lymphocytes remained distinct in all cases. However, it should be noted that also the EnVision TM + technique showed progressive fading of the CD5 staining when the fixation was longer than 24 hours. Moreover, with the EnVision TM + system the Ber-H2/CD30-which unpredictably works in overfixed material 5 22 -continued to produce vivid staining even in samples soaked in formalin for one week ( fig 5) . In all instances, the detected antigens showed their proper location (at the membrane or cytoplasmic level) and the staining appeared stable with time when the sections were exposed to light for three months. Neither background staining nor endogenous peroxidase activity were observed when optimal dilutions of the primary antibodies and the peroxidase inhibition system of the EnVision TM + package were used (figs 2-12).
As shown in tables 1 and 2, no significant diVerences were observed in terms of sensitivity between the EnVision TM + and CSA methods. Only with the antibody against cyclin D1 did the latter indeed appear superior, producing a clear cut positivity which was never detected with the EnVision TM + system. When the immunohistochemical procedures were carried out automatically by the TechMate 500 machine, the results remained superior to those provided by the APAAP, LSAB, and SABC methods, as well as those of the specifically developed ChemMate TM technique. On economic grounds, although the Envision TM + system was 20% more expensive than the APAAP , LSAB, and SABC detection methods, the final cost per test was 35-60% less, thanks to the much higher dilution of the primary antibody, which allowed two to five more preparations to be stained with the same amount of reagent. Comparison with the 
ChemMate
TM was even more favourable, the final cost per test with the Envision TM + system being 45-68% less depending on the dilution of the primary antibody. Only the CSA method, which allowed the same dilutions of the primaries, appeared cheaper than the Envision TM + system; however, the time required to immunostain the slides with the CSA method was longer than with the Envision TM + system 
Assessment of the EnVision
TM + system 509 (five hours v two hours). Thus when the investigation was carried out manually the former incurred a significant extra cost owing to the prolonged involvement of the technical staV.
Discussion
Our results show that the EnVision TM + system is a very sensitive method that usually allows high dilutions of the primary antibodies while maintaining the specificity of the reaction. These advantages become particularly evident when the system is applied manually and its results are compared with those of the most commonly applied methods (the APAAP, LSAB, and SABC techniques). The EnVision TM + system is, however, also readily applicable to immunostainers, with which it gives optimal stains, equivalent to the specifically developed detection systems (for example, the ChemMate TM ). Only the CSA technique, 38 which includes the tyramide based enhancement, appeared to be as eVective as the EnVision TM + system; indeed with the anti-cyclin D1 monoclonal antibody it represented the gold standard.
Besides allowing cheaper immunohistochemical assays-as shown by comparative analysis of the cost per test with the other methods employed-the high dilutions of the primary antibody achieved by the EnVision TM + system also enable more reliable results to be obtained, since very high dilutions prevent background staining, formation of electrostatic or other non-immunological non-specific bonds, or unexpected cross reactivities (especially with polyclonal antibodies). 4 In addition, the immunostains obtained with the EnVision TM + system do not seem to be influenced either by the fixation employed or by its accuracy-in our hands, analogous findings were observed in samples soaked both in formalin (for various lengths of time) and B5, as well as in B5 fixed, EDTA decalcified bone marrow biopsies. This positive eVect should probably be interpreted as a combination of two factors-the system sensitivity on the one hand, and the type of antigen exposure performed 22 on the other. It is important to emphasise that the use of the EnVision TM + system does not influence or have a negative eVect on previously developed and optimised antigen retrieval techniques 23 24 : on the contrary it allows even higher dilutions to be achieved.
The EnVision TM + system also helps in overcoming the problems frequently encountered with some critical antibodies (for example, anti-CD5, Ber-H2/CD30), 5 22 where reactivity on routine sections depends both on the amount of the target molecule present in the tissue and on antigen preservation; the latter in turn is largely determined by how the sample has been treated.
Finally, the EnVision TM + system provides some additional advantages which are related to its intrinsic structural characteristics, such as the lack of endogenous biotin activity, and to the reduction of the staV workload and assay time.
In the light of these results, we think that the EnVision TM + method represents a powerful tool both for daily routine and for research work, which can contribute to the standardisation of immunohistochemical techniques.
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